Publish your Oncology research fast, openly and without restrictions

Submit now to F1000Research

Rapid, open publication is fundamental in complex areas of research like Oncology, where immediate access to robust science is crucial for improving the prevention, detection and treatment of Cancer.

F1000Research's innovative publication model enables the rapid and transparent dissemination of research by providing fast, open publication alongside immediate access to any underlying data, software code and resources. Our Open Access platform allows researchers to publish a wide range of research outputs - from traditional Research Articles to more unique formats, such as Study Protocols, Data Notes, and Method Articles. Additionally, all articles undergo transparent, invited post-publication peer review before being indexed in PubMed Central, MEDLINE and Scopus, with expert reviews freely available for anyone to read. 

We welcome articles covering all areas of Oncology including, but not limited to:

  • Cancer Diagnosis and Prognosis
  • Cancer Biology
  • Clinical Oncology
  • Cancer Epidemiology & Prevention
  • Cancer Surgery & Therapy
  • Survivorship

Our unique publication model, combined with our progressive Open Data Policy, makes F1000Research the perfect home for transparent, reproducible Oncology research.

Submit now 

Instructions for authors

Ready to submit your article? Read our author guidelines now, to ensure you’ve prepared your article correctly for submission to F1000Research.
Read now

Featured articles

Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients

Traditional preclinical and animal-based drug discovery strategies have high clinical failure rates. Ex-vivo approaches address intra-tumoral and inter-patient variability earlier in drug discovery. High-grade gliomas could benefit significantly from ex-vivo approaches. The GliExP platform has been developed to maintain GSC populations using fresh surgical tissue. GliExP has been optimized to screen small molecule therapeutics and preclinical compounds against tumors from 18 different patients. Our data provides a strong basis to incorporate combination-based oncology therapeutics in tandem with standard-of-care therapies as an important preclinical alternative to murine models to identify effective treatment strategies for individual gliomas.
Read the article

Case Report: Basaloid Squamous Cell Carcinoma of the Tongue

Basaloid squamous cell carcinoma (BSCC) is a rare type of squamous cell carcinoma (SCC) that affects the upper aerodigestive tract, particularly the hypopharynx, tonsil, supraglottic larynx, tongue (base), and head-neck regions. It is similar to conventional SCC but has a poorer prognosis. Histopathology and immunohistochemistry play a crucial role in diagnosing such tumors. Here we present the case of a 70-year-old male diagnosed with BSCC involving the tongue.
Read the article

Differentiation of invasive ductal and lobular carcinoma of the breast using MRI radiomic features: a pilot study

Breast cancer is a leading cause of cancer-related deaths among women. Early and precise identification and differentiation of breast lesions are crucial for clinical management. This retrospective study aimed to test the accuracy of radiomic features (RF) extracted from dynamic contrast-enhanced Magnetic Resonance Imaging (DCE MRI) in distinguishing between invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC). The study included 30 patients with IDC and 28 patients with ILC. It showed that MRI-based RF derived from DCE sequences can be effectively used in clinical settings to differentiate malignant breast lesions such as IDC and ILC without requiring intrusive procedures.
Read the article

Why publish with F1000Research

  • Maximize the reach of your work with open publication as standard
  • Once published, your article will undergo transparent open peer-review that puts you at the centre of the publishing process, whilst allowing your research to reach policymakers, industry, and practitioners
  • Tell the full story of your research by publishing a range of articles including Data Notes, Software Tool Articles and Case Reports, alongside Living Systematic Reviews and Research Articles. We welcome both confirmatory and negative results, as well as null studies.
  • Boost the discoverability of your research with inclusion in Scopus, MEDLINE, PubMed, Google Scholar and more
  • Support a more transparent, accessible future for academic research

Ready to submit?

We've prepared guidelines for every article type we publish, from Research Articles to Data Notes. Check the relevant instructions for authors to ensure that you've prepared your paper correctly for submission to F1000Research
Read Now

Download our FAIR Data Guide

Learn more about how to make your data Finable, Accessible, Interoperable, and Reusable, with our quick guide for researchers.
Download now

Join our mailing list

There’s always lots going on at F1000Research, and we’d love to tell you all about it. Be the first to know about our special offers, calls for papers, exclusive content, new developments, and more by signing up to our mailing list today.
Sign up now

The latest Tweets from @F1000Research